Heartburn Drugs and Cancer: What Are the Risks?

By | September 27, 2019

Valisure: “Valisure Citizen Petition on Ranitidine.”

Sandoz Inc.: “Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product.”

Bloomberg: “Carcinogen in Zantac Leads to Another Shipment Halt, Recall.”

Health Canada: “Health Canada requests that companies stop distributing ranitidine drugs in Canada while it assesses NDMA; some products being recalled.”

FDA: “Statement alerting patients and health care professionals of NDMA found in samples of ranitidine.”

Carcinogenesis: “Genotoxic effects in rodents given high oral doses of ranitidine and sodium nitrite,” “Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.”

David Light, CEO, Valisure.

David Gortler, PharmD, associate professor of pharmacology, Georgetown University.

WebMD Health